Sight Sciences Business Summary

Sight Sciences, Inc. (SGHT) is an ophthalmic medical device company that generates revenue through the development and commercialization of interventional technologies for the treatment of glaucoma and dry eye disease. The company operates through two primary segments: Surgical Glaucoma, featuring the OMNI and SION Surgical Systems for minimally invasive glaucoma surgery (MIGS), and Dry Eye, centered on the TearCare System for treating meibomian gland dysfunction. While revenue is primarily driven by high-margin device sales, the company is transitioning its Dry Eye segment toward a recurring revenue model as it secures expanded Medicare and private insurance reimbursement. Sight Sciences competes directly with industry incumbents such as Glaukos, Alcon, and Nova Eye Medical, positioning itself as a specialized innovator focused on "interventional" care paradigms designed to replace traditional, medication-heavy treatment protocols with procedural efficiency. The company was founded in 2011 by brothers Paul Badawi and David Badawi, M.D., who serve as Chief Executive Officer and Chief Technology Officer, respectively, blending strategic business leadership with clinical expertise. The executive team includes Chief Operating Officer Alison Bauerlein, a co-founder of Inogen with a track record of scaling med-tech organizations to over $350 million in annual sales, and Chief Financial Officer James Rodberg, who brings extensive finance experience from Abbott Laboratories and St. Jude Medical. Sight Sciences is governed by a board chaired by Staffan Encrantz and includes notable directors such as Gerhard F. Burbach, former CEO of Thoratec. Major institutional backers include Allegro Investment Fund, KCK Group, BlackRock, and Vanguard, reflecting significant institutional interest in the company’s trajectory toward cash flow breakeven and market leadership in the ophthalmic sector.